TRCT
APGE icon

Tower Research Capital (TRC)’s Apogee Therapeutics APGE Stock Holding History

Tower Research Capital (TRC)’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$521K Buy
6,190
+2,520
+69% +$183K 0.01% 884
2025
Q4 		$277K Buy
3,670
+706
+24% +$44.5K 0.01% 1208
2025
Q3 		$118K Sell
2,964
-5,455
-65% -$208K ﹤0.01% 1872
2025
Q2 		$366K Buy
8,419
+7,434
+755% +$283K 0.01% 1247
2025
Q1 		$36.8K Sell
985
-5,302
-84% -$205K ﹤0.01% 2453
2024
Q4 		$285K Buy
6,287
+4,910
+357% +$250K 0.01% 1447
2024
Q3 		$80.9K Sell
1,377
-4,654
-77% -$223K ﹤0.01% 2392
2024
Q2 		$237K Buy
6,031
+5,775
+2,256% +$280K ﹤0.01% 1933
2024
Q1 		$17K Sell
256
-7,570
-97% -$331K ﹤0.01% 3142
2023
Q4 		$219K Buy
7,826
+7,361
+1,583% +$148K ﹤0.01% 2028
2023
Q3 		$9.9K Buy
+465
New +$10.2K ﹤0.01% 4168

Other funds holding APGE

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Tower Research Capital (TRC)'s APGE Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Apogee Therapeutics (APGE) stake by 69% in Q1 2026, buying an estimated $183K and bringing the position to 6,190 shares worth $521K. The position accounts for 0.01% of the portfolio, ranked #884.

Tower Research Capital (TRC) first reported a position in APGE in Q3 2023 and has held it in 11 quarters since. 224 funds tracked by Wall St. Rank hold APGE as of Q1 2026.

  • Tower Research Capital (TRC) held 6,190 shares of Apogee Therapeutics worth $521K as of Q1 2026.
  • Tower Research Capital (TRC) bought 2,520 Apogee Therapeutics shares in Q1 2026, an estimated $183K.
  • Apogee Therapeutics made up 0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #884 holding.
  • Tower Research Capital (TRC) first reported a position in Apogee Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 224 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.